Cutaneous Toxicities Associated with Immune Checkpoint Inhibitors: An Observational, Pharmacovigilance Study-Reference-Cited by-同舟云学术

Cutaneous Toxicities Associated with Immune Checkpoint Inhibitors: An Observational, Pharmacovigilance Study

Published:2022-11 Issue:11 Volume:142 Page:2896-2908.e4
ISSN:0022-202X
Container-title:Journal of Investigative Dermatology
language:en
Short-container-title:Journal of Investigative Dermatology

Author:

Le Thomas K.^ORCID,Brown Isabelle^ORCID,Goldberg Rebecca^ORCID,Taylor Matthew T.^ORCID,Deng Junwen^ORCID,Parthasarathy Varsha^ORCID,Bordeaux Zachary A.^ORCID,Alphonse Martin Prince^ORCID,Kwatra Madan M.^ORCID,Naranbhai Vivek^ORCID,Gusev Alexander^ORCID,Alhariri Jihad^ORCID,LeBoeuf Nicole R.^ORCID,Reynolds Kerry L.^ORCID,Cappelli Laura C.^ORCID,Naidoo Jarushka^ORCID,Brahmer Julie R.^ORCID,Kang Sewon^ORCID,Semenov Yevgeniy R.^ORCID,Kwatra Shawn G.^ORCID

Funder

Magyar Tüdőgyógyász Társaság

National Institutes of Health

National Institute of Arthritis and Musculoskeletal and Skin Diseases

World Health Organization

Publisher

Elsevier BV

Subject

Cell Biology,Dermatology,Molecular Biology,Biochemistry

Reference49 articles.

1. Safety of immune checkpoint inhibitor rechallenge after discontinuation for grade ≥2 immune-related adverse events in patients with cancer [published correction appears in J Immunother Cancer 2021;9:1];Allouchery;J Immunother Cancer,2020

2. Occurrences and outcomes of immune checkpoint inhibitors-induced vitiligo in cancer patients: A retrospective cohort study;Babai;Drug Saf,2020